FN2 Earnings Intelligence
BioMarin Pharmaceutical Inc. income statement (quarterly)
BioMarin Pharmaceutical Inc. (BMRN) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $1,048.8 | $1,213.8 | $1,250.1 | $2,222.4 | $874 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $745.1 | $825.4 | $776.1 | $766.2 | $989.7 |
| % Growth | - | - | - | - | - |
| Gross Profit | $593.6 | $675.3 | $636 | $571.2 | $786.9 |
| % Margin | 79.7% | 81.8% | 82.0% | 74.6% | 79.5% |
| EBITDA | $246 | $287.5 | -$36.1 | $146.1 | $120.5 |
| % Margin | 33.0% | 34.8% | -4.7% | 19.1% | 12.2% |
| Net Income | $185.7 | $240.5 | -$30.7 | $105.5 | $44.8 |
| % Margin | 24.9% | 29.1% | -4.0% | 13.8% | 4.5% |
| Diluted EPS | $0.95 | $1.23 | -$0.16 | $0.54 | $0.23 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | $174.4 | - | - | $220.7 | - |
| CapEx | $16.8 | - | - | $20.9 | - |
| Free Cash Flow | $157.6 | - | - | $199.7 | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue | $745.1 | $825.4 | $776.1 | $766.2 | $989.7 |
| Gross Profit | $593.6 | $675.3 | $636 | $571.2 | $786.9 |
| EBITDA | $246 | $287.5 | -$36.1 | $146.1 | $120.5 |
| Net Income | $185.7 | $240.5 | -$30.7 | $105.5 | $44.8 |
| Diluted EPS | $0.95 | $1.23 | -$0.16 | $0.54 | $0.23 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,048.8 | $1,213.8 | $1,250.1 | $2,222.4 | $874 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | $1,430.3 | $3,527.9 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $174.4 | - | - | $220.7 | - |
| Capital Expenditure | $16.8 | - | - | $20.9 | - |
| Free Cash Flow | $157.6 | - | - | $199.7 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 79.7% | 81.8% | 82.0% | 74.6% | 79.5% |
| EBITDA Margin | 33.0% | 34.8% | -4.7% | 19.1% | 12.2% |
| Net Margin | 24.9% | 29.1% | -4.0% | 13.8% | 4.5% |
| FCF Margin | 21.2% | - | - | 26.1% | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the BMRN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.